Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies

(2019) Sandra M. M. Irenaeus et al.   INTERNATIONAL JOURNAL OF CANCER

Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists

(2019) Carole Bourquin et al.   PHARMACOLOGICAL RESEARCH

Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

(2019) Stefanie R. Mullins et al.   Journal for ImmunoTherapy of Cancer

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck

(2018) Robert L. Ferris et al.   JAMA Oncology

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

(2018) Melody Smith et al.   OncoImmunology

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

(2017) Huju Chi et al.   Frontiers in Pharmacology

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

(2016) Laura Q.M. Chow et al.   CLINICAL CANCER RESEARCH

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

(2015) A. H. Rook et al.   BLOOD

TLR7/8 agonists promote NK–DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma

(2015) Zhixia Zhou et al.   CANCER LETTERS

Spontaneous hepatic haemorrhage: a review of pathogenesis, aetiology and treatment

(2015) Sanket Srinivasa et al.   HPB

Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors

(2015) Sebastian Schölch et al.   Oncotarget

Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma

(2014) Auris O. Huen et al.   CURRENT OPINION IN ONCOLOGY

Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

(2014) Manisha Singh et al.   JOURNAL OF IMMUNOLOGY

Spontaneous rupture of hepatic metastasis from small cell neuroendocrine carcinoma of maxillary sinus

(2014) Yun-fei Duan et al.   World Journal of Surgical Oncology

Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction

(2014) A Nicole Desch et al.   Nature Communications

Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial

(2014) A. M. Salazar et al.   Cancer Immunology Research

Prognostic Impact of Spontaneous Tumor Rupture in Patients With Hepatocellular Carcinoma

(2013) Taku Aoki et al.   ANNALS OF SURGERY

RNA recognition by human TLR8 can lead to autoimmune inflammation

(2013) Cristiana Guiducci et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The Yin and Yang of Toll-like receptors in cancer

(2013) J-P Pradere et al.   ONCOGENE

Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma

(2013) Qian Zhu   WORLD JOURNAL OF GASTROENTEROLOGY

Systematic review of haemorrhage and rupture of hepatocellular adenomas

(2012) S. M. van Aalten et al.   BRITISH JOURNAL OF SURGERY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST